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Available online 17 December 2015Introduction: The gastro-intestinal hormone glucose-dependent insulinotropic polypeptide (GIP) potentiates
glucose-induced insulin secretion, with bone anabolic effects through GIP receptor (GIPR) in animal models.
We explore its potential in humans by analyzing association between polymorphisms (SNPs) in the GIP and
GIPR genes with bone phenotypes in young and elderly women.
Methods: Association between GIP (rs2291725) and GIPR (rs10423928) and BMD, bone mineral content (BMC),
bonemicroarchitecture, fracture and body composition was analyzed in the OPRA (75y, n= 1044) and PEAK-25
(25y; n = 1061) cohorts and serum-GIP in OPRA.
Results: The GIP receptor AA-genotype was associated with lower ultrasound values in young women (BUA p=
0.011; SI p= 0.030), with no association to bone phenotypes in the elderly. In the elderly, the GIPwas associated
with lower ultrasound (GG vs. AA; SOS padj=0.021) and lower femoral neck BMDand BMC after adjusting for fat
mass (padj = 0.016 and padj = 0.03). In young women, neither GIPR nor GIP associated with other bone pheno-
types including spine trabecular bone score. In the elderly, neither SNP associated with fracture. GIPwas associ-
ated with body composition only in Peak-25; GIPR was not associated with body composition in either cohort.
Serum-GIP levels (in elderly) were not associated with bone phenotypes, however lower levels were associated
with the GIPR A-allele (β=−6.93; padj = 0.03).
Conclusions: This ﬁrst exploratory association study between polymorphisms in GIP and GIPR in relation to bone
phenotypes and serum-GIP in women at different ages indicates a possible, albeit complex link between glucose
metabolism genes and bone, while recognizing that further studies are warranted.








Osteoporosis is a silent and progressive systemic skeletal disorder
resulting in low bonemineral density (BMD)with fracture as its associ-
ated clinical consequence (Consensus Development Conference, 1993).
The maintenance of skeletal strength through bone remodeling is
regulated through complex interactions between bone cells and
endocrine cells (Rosen and Klibanski, 2009). There is evidence for the
role of gastro-intestinal hormones secreted in response to food intake, SkåneUniversity Hospital, 205
n).
. This is an open access article underin the maintenance of skeletal integrity and altered proﬁles of bone
turnover-markers have been observed in the aftermath of meal inges-
tion (Elnenaei et al., 2010; Henriksen et al., 2003). Glucose-dependent
insulinotropic polypeptide (also known as gastric inhibitory polypep-
tide (GIP)) is one such gastro-intestinal hormone. Secreted by K cells
in the small intestine, GIP potentiates glucose-induced insulin secretion
from pancreatic β-cells leading to reduced blood glucose levels (Saxena
et al., 2010). In vitro studies have shown that GIP inhibits osteoclast dif-
ferentiation and activity via a directmechanismwhichmay lead to a net
effect of increased bone mass, although the effects of GIP could also be
mediated, at least in part, by variation in insulin secretion (Fulzele and
Clemens, 2012); in rats, administration of GIP reduces bone loss
after ovariectomy (Bollag et al., 2001; Bollag et al., 2000; Zhong et al.,
2007).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oclasts as well as a wide range of tissues including adipocytes, pancreas,
lungs, kidney and thyroid (Bollag et al., 2000; Zhong et al., 2007). Stud-
ies of transgenic mice overexpressing GIP show higher BMD and bone
mineral content (BMC) than controls while in addition, they have ele-
vated serum levels of GIP and total osteocalcin (Ding et al., 2008). Fur-
thermore, in these mice, an age dependent decrease in GIPR
expression has also been observed. Conversely, knockout mice deﬁcient
in GIPR have deranged cortical microarchitecture of bone leading to re-
duced bone ‘quality’ and strength and low fatmass (Mieczkowska et al.,
2013). Taken together these observations represent one aspect of the
complex shared molecular mechanisms between osteoporosis and dia-
betes. Type 1 diabetes (T1D) is associated with low BMD and increased
fracture risk (Vestergaard et al., 2005) while type 2 diabetes (T2D),
with its increased risk of fracture despite normal bone mass
(Janghorbani et al., 2007; Nicodemus and Folsom, 2001), is compli-
cated by the complex relationship between body weight, osteoporo-
sis and T2D.
In a meta-analysis of genome-wide association studies, a variant
(rs10423928) in the GIPR gene has been found to be associated with el-
evated postprandial glucose and insulin (Saxena et al., 2010) as well as
lean body composition including decreased BMI, lean mass and waist
circumference (Lyssenko et al., 2011), hence its selection for this
study. Only one study however has investigated GIPR variation in rela-
tion to BMD; reporting that a functional SNP in linkage disequilibrium
with rs10423928was associatedwith low BMD in early postmenopaus-
alwomen (Torekov et al., 2014). To date there have been nopopulation-
based studies investigating association of variants in the GIP gene with
bone phenotypes.
The primary aim of our study was to investigate the association of
SNPs in the GIP and GIPR genes with skeletal phenotypes beyond bone
density (BMC, bone microarchitecture, fracture), body composition
and serum GIP level. Since menopausal (estrogen) statusmay inﬂuence
the association, the study was performed in two population-based co-
horts consisting of 75 year and 25 year old women.2. Materials and methods
2.1. Subjects
Two population based cohorts of Swedish women living in Malmö,
Sweden were studied; the Osteoporosis Prospective Risk Assessment
cohort (OPRA) consisting of 1044 elderly women aged 75 at inclusion
and followed-up at 5 years (n = 715) and 10 years (n = 382) and the
PEAK-25 cohort consisting of 1061 women all 25 years old at inclusion.
Details of the cohorts have been published elsewhere (Gerdhem et al.,
2004; McGuigan et al., 2007). All study participants gave written in-
formed consent and the studywas approved by the Regional Ethical Re-
view Board in Lund, Sweden.2.2. DXA — bone phenotypes and body composition
BMDwasmeasured for total body (TB), femoral neck (FN), and lum-
bar spine (LS) using dual-energy X-ray absorptiometry (DXA) (Lunar
Prodigy: PEAK-25; Lunar DPX-L: OPRA (Lunar Corporation, Madison,
WI, USA). Total body fat mass (FM) and leanmass (LM) were also mea-
sured by using DXA. All measurements were performed using the same
instrument. At baseline, software versions 1.33 and 1.35 (OPRA) and
2.05, 2.15, 3.60, 5.70 and 7.70 (PEAK-25) were used. Version 4.7e was
used for OPRA 10 year follow-up. Calibrations were performed daily
using a manufacturer supplied phantom. Precision (coefﬁcient of varia-
tion (CV)) for DXA scanning was 0.94% (TB), 1.45% (LS) and 4.01% (FN)
in the OPRA cohort (Lenora et al., 2010) and 0.90% (FN) and 0.65% (LS)
in PEAK-25 (Callreus et al., 2012).2.3. Bone microarchitecture at the spine and heel
We also assessed aspects of bone strength as reﬂected by
microarchitecture (or bone ‘quality’) measured by quantitative ultra-
sound (QUS): speed of sound (SoS) (m/s), broadband ultrasound atten-
uation (BUA) (dB/MHz), and stiffness index (SI). Measurements were
performed using the Lunar Achilles (R) system (Lunar Corporation
Madison, WI, USA) in both cohorts. The CV was 1.5% for derivatives of
BUA and SoS (Karlsson et al., 1998). Daily calibrations were performed.
Microarchitecture in the spine was measured using the trabecular
bone score (TBS), a novel approach applied to the DXA image. Due to
technical limitations TBS could not be calculated from the Lunar DPX-
L, therefore spine acquisitions were available only for the PEAK-25 co-
hort. Posteroanterior spine acquisitions were analyzed using the
manufacture's software (Encore 2004; GE Medical-Lunar, Madison,
WI) and a standardized protocol (Hans et al., 2011). TBS was calculated
as the mean value of the individual measurements for each vertebra (L1
to L4).
2.4. Incident fracture
In the OPRA cohort information on incident fractures was obtained
through questionnaires at 1, 3, 5 and 10 years after the baseline investi-
gation. These fractures and all fractures occurring until October 2012
providing a maximum follow-up for fracture of 17.2 years (mean 13.1
years) were veriﬁed in ﬁles at the Department of Radiology, Skåne Uni-
versity Hospital, Malmö, Sweden. We focused on analyzing “Any Inci-
dent Fracture” as a single category. This category included hip, distal
radius, vertebra, shoulder, pelvis and proximal tibia fractures. Fractures
of the face, hands and feet were excluded. The majority of fractures
(N99%) were attributed to low energy trauma. In the PEAK-25 cohort,
fracture incidencewas not analyzed due to the lownumbers of fractures
occurring at this age.
2.5. Serum GIP
SerumGIP (s-GIPmeasurementswere available only in the OPRA co-
hort; at 10 year follow-up. Levels of s-GIP were successfully measured
for n = 363/382 participants. s-GIP was measured in fasting samples
using a human GIP (Total) ELISA kit (Millipore, R&D Systems, Abingdon,
UK) (Ahlqvist et al., 2013). The assay was performed following the
manufacturer's instructions. No samples fell below the lower limit of de-
tection (8.2 pg/ml). The inter-assay CVwas 2–6% while CV for the study
samples was 4.3–5.6.
2.6. Genotyping
Total genomic DNA was isolated from blood using the QIAamp 96
DNA blood kit (Qiagen, Valencia, CA, USA) according to the
manufacturer's instructions. In this study, we analyzed rs2291725 (G/
A, S103G) located in exon 4 of GIP and rs10423928 (T/A) in intron 12
of GIPR (Table 1). The GIP SNP rs2291725 was chosen since it is a high
frequencymissense variation in theGIP gene changing amino acid num-
ber 103 in the GIP protein (Ser to Gly). The rationale for selection of the
GIPR SNP lies in the fact that in a combined analysis of several GWAS
studies the risk genotype of rs10423928 showed impaired insulin secre-
tion. This GIPR SNP is in strong linkage disequilibrium (r2 = 0.99) with
the non-synonymous SNP rs1800437 (E354Q) analyzed in the study by
Torekov et al. (2014). Consequently the two SNPs reﬂect the same ge-
netic variation in the gene.
From those who agreed to provide whole blood for DNA analyses, a
total of 990women fromOPRA and 992women from PEAK-25were ge-
notyped successfully using TaqMan (ABI, Foster City, USA). Approxi-
mately 3% of the samples from each cohort were genotyped in
duplicate with 100% concordance. Both polymorphisms conformed to
Hardy–Weinberg equilibrium and the minor allele frequencies did not
Table 1
Genotype and allele frequencies of the polymorphisms studied.
SNP_Gene OPRA MAF PEAK-25 MAF
TT TA AA TT TA AA
rs10423928 610 335 45 0.21 606 324 60 0.22
GIPR (61.6%) (33.8%) (4.6%) (61.2%) (32.7%) (6.1%)
GG GA AA GG GA AA
rs2291725 271 493 226 0.47 260 507 225 0.48
GIP (27.4%) (49.8%) (22.8%) (26.2%) (51.1%) (22.7%)
GIP — gastric inhibitory polypeptide; GIPR— gastric inhibitory polypeptide receptor.
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cies did not differ between cohorts.
2.7. Statistical analyses
All statistical analyses were performed using SPSS version 22 (IBM
Corp., NY, USA). To analyze association between genotypes and fracture,
the χ2 test was used. Logistic regression analysis with adjustment for fat
mass and smoking were also used. Unadjusted analyses for continuous
variables (BMD, BMC, ultrasound, trabecular bone score and body com-
position) were performed using the Kruskal-Wallis to test for all three
genotypes. Genotype association with continuous variables was also
performed using regression analysis. Multivariate regression analysis
was used to identify confounding factors. Therefore bone phenotypes
were adjusted for fat mass (trabecular bone score was additionally ad-
justed for lumbar spine BMD) and body composition phenotypes ad-
justed for smoking. The results were not appreciable different when
corrected for diabetes, therefore in the presented results women who
reported having diabetes (either type I or type II; n = 69) were not ex-
cluded from the analyses. A priori power analyses, assuming a SD of
0.13 g/cm2 in BMD, indicated that our sample size allowed N80%
power to detect differences of 0.065 g/cm2 between genotypes assum-
ing a minor allele frequency of N0.21. Nominal signiﬁcance was consid-
ered with associations of p b 0.05. We report the uncorrected p-values,
acknowledging that multiple tests were performed.
3. Results
The characteristics of the women from the two differently aged
cohorts have been published previously (Gerdhem et al., 2004;
McGuigan et al., 2007). Brieﬂy, elderly women from the OPRA cohort,
as expected, had higher BMI and fat mass and lower lean mass and
bone mineral density than the young women from PEAK-25 cohort
(Supplementary Table 1). Both fat and leanmasswere strongly positive-
ly associated with BMD and QUS (Callreus et al., 2012; Garg et al., 2014;
Gerdhem et al., 2003).
Mean serum GIP level in the OPRA cohort at 10 year follow-up was
58.5 pg/ml [SD 33.8]. There was no association between GIP level and
any of the bone phenotypes measured at 10 y follow-up, although fem-
oral neck BMD and BMCwere lower in the highest GIP tertile compared
to the lowest (BMD: 0.693 vs 0.684, p= 0.87; BMC: 3.564 vs 3.517, p=
0.94). Similarly, body composition phenotypeswere not associatedwith
serumGIP despite fat and leanmass showing a tendency towards being
higher in the highest GIP tertile (TB-fat: 24.2 vs 25.4, p=0. 57; TB-lean:
35.7 vs 36.1, p = 0.39).
The GIP polymorphism was not associated with serum GIP. Howev-
er, as previously reported (Lyssenko et al., 2011), the variant ‘A’ allele of
the GIPR polymorphismwas associated with lower serum GIP in a dose
dependent fashion (TT: 54.8 vs TA: 46.1 vs AA: 41.9; p = 0.019) even
after adjustment for fat mass (β=−6.93 (SE 3.19); padj = 0.03).
In the elderly women, GIP genotype was associated with lower BMD
at the femoral neck (padj= 0.016), BMC at total body (padj= 0.020) and
femoral neck (padj = 0.030), as well as lower QUS_SoS values (padj =0.021) at baseline (Table 2) and at 10 year follow-up (data not
shown). Conversely, in the young women neither BMD nor BMC were
associated with this SNP. Neither did bone properties reﬂecting
microarchitecture (i.e. QUS at the calcaneus and TBS at the spine), differ
between genotypes (Table 2).
Variation in GIPRwas not associated with BMD or BMC in either co-
hort (Table 3). In PEAK-25, although trabecular bone score did not differ
with genotype, women carrying the minor allele had lower calcaneus
QUS values, but only BUA and SI reached nominal signiﬁcance and
remained after adjustment for fat mass (BUA β = −1.63 (SE 0.59),
padj = 0.006; SI β = −1.86 (SE 0.83), padj = 0.026). The results
remained similar after further adjustment for femoral neck BMD. Con-
versely, although non-signiﬁcant, the trend was towards higher QUS
values in the elderly women (Table 3).
In PEAK-25, a general trend for association between weight, BMI, fat
and lean mass was observed with the GIP polymorphism (Table 2).
Nominal signiﬁcance was reached for weight and total body fat mass
after adjustment for smoking (padj = 0.031 and 0.026) (Table 2).
There was no association with body composition in OPRA. Variation in
GIPRwas not associated with body composition in either cohort.
Neither GIP nor GIPR SNPs were associated with occurrence of frac-
tures in the OPRA cohort (Table 4).4. Discussion
The basis for this study lies in the role of glucose-insulinotropic pep-
tide (GIP) hormone in the regulation of insulin secretion as well as its
anabolic effect on osteoblasts and inhibition of osteoclasts (Tsukiyama
et al., 2006; Xie et al., 2005). Transgenic mice over-expressing GIP
have increased cortical bone mass while GIP also appears to prevent
age related decline in bone mass and bone strength (Ding et al., 2008).
Thus GIP and the receptor to GIP (GIPR) genes are attractive biological
candidates to understand the genetic relationship between type 2 dia-
betes and osteoporosis. In this study, comprising two differently aged
cohorts of women, we investigated if genetic variants in GIP and GIPR
displayed association with phenotypes contributing to bone pheno-
types including bone quantity and structure.
In the present study, BMD and BMC were not associated with GIPR;
however there was an association, although only in the young
women, with lower calcaneal ultrasound values and this was indepen-
dent of bone density. The absence of an association with bone architec-
ture in the spine however is in line with data from a knock-out mouse
model demonstrating that the effects of GIPR deﬁciency on bone
microarchitecture (Mieczkowska et al., 2013) differ between predomi-
nantly cortical and trabecular skeletal sites (Gaudin-Audrain et al.,
2013).
In the recent study fromDenmark, aGIPR SNP (rs1800437), in strong
linkage disequilibrium with the rs10423928 SNP used here, was ana-
lyzed. They observed an associationwith lower BMD and increased frac-
ture risk which is in contrast with our ﬁndings. Since one would expect
Swedish and Danish to be genetically similar, a possible explanation for
this divergent ﬁnding is that the Danish women were perimenopausal
suggesting that GIPR has amore important role in the immediate period
Table 2
Association of GIP rs2291725 with bone phenotypes and body composition.
OPRA GG GA AA β-Value (adj)a pb pc (adj)
BMD total body (g/cm2) 1.010 (0.945–1.074) 1.002 (0.943–1.067) 0.994 (0.934–1.056) −0.01 (−0.01 to 0.001) 0.30 0.090
BMD femoral neck (g/cm2) 0.761 (0.677–0.865) 0.748 (0.668–0.846) 0.733 (0.641–0.831) −0.01 (−0.03 to−0.003) 0.11 0.016
BMC total body (g) 2085 (1832–2310) 2026 (1812–2260) 1977 (1765–2210) −31 (−58 to−5) 0.11 0.020
BMC femoral neck (g) 3.8 (3.26–4.6) 3.8 (3.30–4.4) 3.7 (3.18–4.4) −0.1(−0.2 to−0.01) 0.21 0.030
QUS_BUA (dB/MHz) 101.4 (94.1–108.0) 103.0 (96.2–108.7) 100.7 (94.1–107.7) −0.1 (−1.1 to 0.8) 0.11 0.76
QUS_SoS (m/s) 1525 (1505–1540) 1523 (1508–1541) 1516 (1501–1537) −3.1 (−5.7 to−0.4) 0.032 0.021
QUS_Stiffness Index 71.2 (62.1–80.2) 72.0 (64.0–81.3) 69.0 (59.4–79.1) −0.76 (−1.99 to 0.49) 0.043 0.23
Weight (kg) 67 (59–75) 67 (60–75) 67 (61–76) −0.01 (−1.03 to 1.01) 0.88 0.98
BMI (kg/m2) 26.1 (23.7–28.6) 25.9 (23.3–28.7) 26.0 (23.4–28.7) −0.03 (−0.40 to 0.34) 0.83 0.86
Total body fat mass (kg) 25.57 (20.54–31.13) 25.62 (20.66–31.19) 26.47 (21.03–31.77) 173.45 (−557.99 to 904.88) 0.79 0.64
Total body lean mass (kg) 36.98 (34.80–40.21) 36.82 (34.59–39.74) 37.20 (34.84–39.14) −108.83 (−476.28 to 258.61) 0.86 0.56
PEAK-25 GG GA AA β-Value (adj)a Pb Pc (adj)
BMD total body (g/cm2) 1.158 (1.115–1.222) 1.177 (1.126–1.221) 1.168 (1.128–1.229) 0.003 (−0.003 to 0.01) 0.12 0.32
BMD femoral neck (g/cm2) 1.037 (0.970–1.129) 1.045 (0.976–1.130) 1.052 (0.962–1.142) 0.001 (−0.01 to 0.01) 0.28 0.79
BMD lumbar spine (g/cm2) 1.226 (1.135–1.298) 1.234 (1.148–1.334) 1.249 (1.143–1.332) 0.01 (−0.004 to 0.02) 0.42 0.21
BMC total body (g) 2534 (2343–2763) 2575 (2336–2846) 2619 (2363–2866) 8.33 (−19.66 to 36.33) 0.39 0.56
BMC femoral neck (g) 4.9 (4.5–5.4) 5.0 (4.5–5.5) 5.1 (4.5–5.6) 0.02 (−0.04 to 0.08) 0.35 0.55
BMC lumbar spine (g) 51.8 (46.8–57.9) 52.7 (47.24–58.5) 53.2 (46.87–59.3) 0.20 (−0.53 to 0.94) 0.69 0.59
QUS_BUA (dB/MHz) 116.1 (110.5–122.0) 116.8 (110.2–123.4) 115.4 (109.1–125.6) −0.2 (−1.2 to 0.8) 0.74 0.70
QUS_SoS (m/s) 1574 (1555–1594) 1570 (1551–1595) 1569 (1546–1598) −1.44 (−4.55 to 1.67) 0.14 0.36
QUS_Stiffness Index 98.3 (90.1–108.6) 97.9 (88.6–108.1) 97.0 (86.6–110.1) −0.53 (−1.93 to 0.88) 0.29 0.46
Trabecular bone scored 1.42 (1.37–1.46) 1.43 (1.38–1.47) 1.42 (1.38–1.46) 0.001 (−0.01 to 0.01) 0.33 0.76
Weight (kg) 63 (57–69) 62 (57–69) 64 (58–72) 1.09 (0.1 to 2.09) 0.16 0.031
BMI (kg/m2) 22.4 (20.7–24.5) 22.2 (20.2–24.6) 22.7 (20.8–25.0) 0.31 (−0.02 to 0.64) 0.09 0.07
Total body fat mass (kg) 19.54 (15.39–24.47) 19.03 (14.99–24.52) 20.40 (15.78–26.89) 837.80 (102.76 to 1572.85) 0.09 0.026
Total body lean mass (kg) 39.86 (37.42–42.86) 40.22 (37.08–43.27) 40.57 (37.42–43.74) 192.58 (−224.09 to 609.25) 0.64 0.37
BMD (bonemineral density), BMC (bonemineral content), QUS (quantitative ultrasound; SoS (speed of sound), BUA (broadband ultrasound attenuation), SI (stiffness index). Values are
median (interquartile range).
a (GG vs. GA vs. AA).
b Kruskal-Wallis.
c Linear regression — adjusted for fat mass.
d Additionally adjusted for fat mass & LS BMD.
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very elderly. GIPR expression is reduced with age (Ding et al., 2008)
which would appear to support this.
In our study, GIPR had an effect on body composition showing small
reductions inweight and fatmass. This is largely in linewith the ﬁndings
of Lyssenko et al. (2011), who also demonstrated that the BMI-lowering
effect of this SNP neutralized the concomitant association with impaired
glucose concentration and GIP-stimulated insulin secretion.Table 3
Association between GIPR (rs10423928) and bone composition.
OPRA TT TA
BMD total body (g/cm2) 0.999 (0.943–1.073) 1.002 (0.934–1.064)
BMD Femoral neck (g/cm2) 0.758 (0.666–0.851) 0.739 (0.655–0.835)
BMC total body (g) 2046 (1798–2285) 2023 (1810–2230)
BMC femoral neck (g) 3.8(3.3–4.5) 3.7 (3.2–4.4)
QUS_BUA (dB/MHz) 101.4 (96.0–108.0) 102.5 (96.0–108.0)
QUS_SoS (m/s) 1521 (1504–1538) 1523 (1506–1541)
QUS_Stiffness Index 70.1 (62.1–79.1) 72.3 (63.0–81.0)
PEAK-25 TT TA
BMD total body (g/cm2) 1.166 (1.124–1.221) 1.177 (1.122–1.225)
BMD femoral neck (g/cm2) 1.040 (0.972–1.130) 1.048 (0.961–1.132)
BMD lumbar spine (g/cm2) 1.232 (1.139–1.322) 1.237 (1.153–1.321)
BMC total body (g) 2562 (2343–2828) 2584 (2345–2841)
BMC Femoral neck (g) 5.0 (4.6–5.5) 5.0 (4.5–5.6)
BMC lumbar spine (g) 52.8 (47.2–58.5) 52.2 (46.9–59.2)
QUS_BUA (dB/MHz) 117.1 (110.4–124.7) 114.6 (109.1–121.5)
QUS_SoS (m/s) 1572 (1552–1597) 1568 (1549–1593)
QUS_Stiffness Index 97.8 (88.9–109.7) 96.4 (86.8–107.0)
Trabecular bone scored 1.43 (1.38–1.47) 1.42 (1.38–1.46)
BMD (bone mineral density), BMC (bone mineral content), QUS (quantitative ultrasound; SoS
values are median (interquartile range).
a (TT vs. TA vs. AA).
b Kruskal-Wallis.
c Adjusted for fat mass (linear regression).
d Additionally adjusted for fat mass & LS BMD.Why the GIPR rather than the GIP SNP was associated with serum
levels of GIP is unclear although decreased receptor activity has been
reported for the GIPR E354Q (rs1800437) variant (Gaudin-Audrain
et al., 2013) which could inﬂuence the cycles of receptor desensitiza-
tion/resensitization. In cultured adipocytes, the receptor has been
shown to be down regulated by GIP stimulation and desensitized to
further GIP stimulation for a prolonged period (Ranganath et al.,
1998).AA β-Value (adj)a pb pc (adj)
1.021 (0.967–1.060) 0.003 (−0.01 to 0.01) 0.56 0.49
0.763 (0.706–0.867) −0.003 (−0.02 to 0.01) 0.44 0.70
2191 (1899–2290) 12 (−20 to 45) 0.26 0.45
3.9 (3.5–4.5) −0.03 (−0.12 to 0.07) 0.21 0.58
103.0 (95.6–110.4) 0.77 (−0.35 to 1.88) 0.62 0.18
1528 (1509–1545) 2.45 (−0.73 to 5.64) 0.38 0.13
72.2 (63.8–85.4) 1.26 (−0.23 to 2.74) 0.45 0.10
AA β-Value (adj)a pb pc (adj)
1.152 (1.115–1.217) 0.002 (−0.01 to 0.01) 0.38 0.57
1.049 (0.960–1.131) 0.001 (−0.01 to 0.01) 0.97 0.83
1.256 (1.164–1.335) 0.01 (−0.01 to 0.02) 0.84 0.20
2506 (2348–2763) 9.72 (−22.31 to 41.75) 0.82 0.55
5.1 (4.6–5.5) 0.03 (−0.04 to 0.10) 0.97 0.34
51.7 (46.1–57.5) 0.2 (−0.64 to 1.04) 0.78 0.64
115.4 (108.8–121.7) −1.63 (−2.79 to−0.47) 0.011 0.006
1567 (1546–1586) −2.77 (−6.40 to 0.87) 0.10 0.14
94.5 (87.3–103.9) −1.86 (−3.49 to−0.22) 0.03 0.026
1.44 (1.38–1.48) 0.001 (−0.01 to 0.01) 0.62 0.84
(speed of sound), BUA (broadband ultrasound attenuation), SI (stiffness index). Reported
Table 4
Association of GIP and GIPR polymorphisms with incident fracturea in OPRA women.
TT TA AA p
rs10423928_GIPR Fracture 312 (62.5%) 165 (33.1%) 22 (4.4%) 0.838
No fracture 298 (60.7%) 170 (34.6%) 23 (4.7%)
GG GA AA p
rs2291725_GIP Fracture 134 (26.9%) 242 (48.6%) 122 (24.5%) 0.450
No fracture 137 (27.8%) 251 (51.0%) 104 (21.1%)
p-Value calculated by the χ2 test.
a Incident fracture of any type (includes hip, distal radius, vertebra, shoulder, pelvis and
proximal tibia fractures).
27G. Garg et al. / Bone Reports 4 (2016) 23–27Serum GIP levels are reported to be increased in postmenopausal
women (Ranganath et al., 1998) and modulated by estrogen replace-
ment therapy (Sztefko et al., 2005), in our study however, GIP does
not appear to be exerting a bone anabolic effect, at least in this elderly
age group.Whether age related differences in sGIP explain our observed
results is uncertain.
The GIP SNP rs2291725 (Gly103Ser) is a functional variant previous-
ly reported to be associated with type 2 diabetes (Chia et al., 2009) but
not yet explored in relation to altered bone phenotypes. In this study,
the GIP polymorphism was adversely associated with components of
bone strength including density, mineral content andmicroarchitecture
in the elderly but not the young women, even after adjustment for fat
mass. The absence of an association with body composition directly
contrasts with the positive association observed speciﬁcally with
weight and fat mass in the young PEAK-25 cohort.
The strengths of this study include being the ﬁrst, to our knowledge,
evaluating the importance ofGIPpolymorphisms in relation to bonephe-
notypes in human cohorts, although a receptor gene polymorphism has
been reported once before. In addition, we have not only evaluated BMD
but also bone strength and related phenotypes. In the elderlywomen,we
also analyzed serumGIP, although aweakness of the investigation is that
this was only available for only 363 individuals, hence the statistical
power to detect association was limited. In addition, serum levels could
not be determined in the young making it difﬁcult to establish potential
interaction between serum GIP levels, bone properties, body composi-
tion and genotype at different ages. A limitation of the study is the fact
that neither of the SNPs has been identiﬁed as major candidate genes
in GWAS for osteoporosis related phenotypes. However, since SNP
based GWAS do not identify all disease risk variants, studies of variants
identiﬁed in related pathways are still warranted. We also acknowledge
that the results must be interpreted with caution, since the associations
are modest, in the absence of stringent adjustment for multiple testing.
Underlying this study is the hypothesized importance of insulin and
glucose metabolism on bone. In our investigation of GIP and GIPR gene
polymorphisms in relation to bone phenotypes in young and old
women our ﬁndings depict a complex relationship between glucose
metabolism genes and bone. In the current setting, it is not possible to
explore the reason for these observations. Further studies in equivalent
populations are merited to explore these associations further.
Supplementary data to this article can be found online at http://dx.
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